Co-Diagnostics, Inc.
About Co-Diagnostics, Inc.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $622.5K
- Net income
- -$46.9M
- Total assets
- $24.7M
- Market cap
- $20.7M
- Gross margin
- 64.3%
- Operating margin
- -8058.8%
- Net margin
- -7533.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $622.5K
- Cost of revenue
- $222.4K
- Gross profit
- $400.1K
- Operating expenses
- $50.6M
- Operating income
- -$50.2M
- Income tax
- -$1.6M
- Net income
- -$46.9M
- EPS (basic)
- $-35.25
- EPS (diluted)
- $-35.25
Balance sheet
- Total assets
- $24.7M
- Current assets
- $13.7M
- Total liabilities
- $4.1M
- Current liabilities
- $3.5M
- Shareholders’ equity
- $20.6M
Cash flow
- Operating cash flow
- -$29.1M
- Investing cash flow
- $26.3M
- Financing cash flow
- $11.8M
- Net cash flow
- $8.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $20.7M
- EPS (diluted)
- $-35.25
- Shares outstanding
- 4.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 12, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $46.9M in FY2025.
- Revenue declined 99% from FY2021 to FY2025.
- Gross margin of 64.3%, net margin -7533.6%.
- Trading 87% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Co-Diagnostics, Inc..
Write a review
News about Co-Diagnostics, Inc.
News & sentiment via Polygon.io
